Genomic Valley

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE574D01010
  • NSEID:
  • BSEID: 539206
INR
44.75
-2.18 (-4.65%)
BSENSE

Nov 20

BSE+NSE Vol: 1.25 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 493236,
    "name": "Genomic Valley",
    "stock_name": "Genomic Valley",
    "full_name": "Genomic Valley Biotech Ltd",
    "name_url": "stocks-analysis/genomic-valley",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "44.75",
    "chg": -2.18,
    "chgp": "-4.65%",
    "dir": -1,
    "prev_price": "46.93",
    "mcapval": "14.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 539206,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 67,
    "indexname": "",
    "isin": "INE574D01010",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "1.25 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/genomic-valley-493236-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [],
    "total": 2,
    "sid": "493236",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/genomic-valley-biotech-493236"
  },
  "announcements": [
    {
      "caption": "Draft Letter of Offer",
      "datetime": "03-Nov-2026",
      "details": "Fintellectual Corporate Advisors Pvt Ltd (\"Manager to the Offer\") has submitted to BSE a copy of Draft Letter of Offer for the attention of the Public Shareholders of Genomic Valley Biotech Ltd (\"Target Company\").",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "02-Nov-2026",
      "details": "Please find enclosed herewith unaudited financial results for the quarter and half year ended on 30th September 2026.",
      "source": "BSE"
    },
    {
      "caption": "Un-Audited Standalone Financial Results For The Quarter And Half Yearly Ended On September 30Th 2026",
      "datetime": "30-Oct-2026",
      "details": "Please find enclosed herewith unaudited standalone financial results for the quarter and half yearly ended on September 30 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
Icon
No Recent News for the Company
stock-recommendationAnnouncement

Draft Letter of Offer

03-Nov-2026 | Source : BSE

Fintellectual Corporate Advisors Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of the Public Shareholders of Genomic Valley Biotech Ltd ("Target Company").

Announcement under Regulation 30 (LODR)-Newspaper Publication

02-Nov-2026 | Source : BSE

Please find enclosed herewith unaudited financial results for the quarter and half year ended on 30th September 2026.

Un-Audited Standalone Financial Results For The Quarter And Half Yearly Ended On September 30Th 2026

30-Oct-2026 | Source : BSE

Please find enclosed herewith unaudited standalone financial results for the quarter and half yearly ended on September 30 2026

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available